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Figure 1 Risk of symptomatic disease and wheelchair use over time in dysferlinopathy. Graphs show the probability of remaining event free during the 
time under study using Cox proportional hazards regression. events are the onset of symptoms (A), the first time a wheelchair is used (B) and the need to 
use a wheelchair full time (C). Survival probabilities significantly different from exercise group 0 are marked with an asterisk (*). For first-time wheelchair 
use (B), this graph shows the results excluding those patients over 50 years of age at the screening visit as including these patients led to a violation of the 
proportional hazards assumption.
Teenage exercise is associated 
with earlier symptom onset in 
dysferlinopathy: a retrospective 
cohort study
IntroductIon
Dysferlinopathy, an autosomal reces-
sive muscular dystrophy caused by DYSF 
mutations, demonstrates a variable pheno-
type and progression rate, with symptom 
onset ranging from first to eighth decade 
and some patients requiring wheelchairs 
for mobility within 10 years, with others 
remaining minimally affected.1
Dysferlinopathy populations have 
previously been described as having an 
unusually high level of presymptomatic 
sporting ability.2 We hypothesised that 
this activity could be related to subse-
quent disease progression and investi-
gated the hypothesis using data from 
the Jain Foundation’s Clinical Outcomes 
Study (COS) of 202 patients with 
dysferlinopathy.1
MethodS
Data were used from 182 of the 202 
patients enrolled in the Jain COS; 10 
dropped out and did not give permis-
sion to use their data and 10 did not fully 
complete the exercise questionnaire.
The questionnaire used in the screening 
visits (online supplementary informa-
tion) between 6 November 2012 and 19 
March 2015 asked about the type, level 
and frequency of all physical activity prior 
to symptom onset. Self-reported age of 
first symptoms, first wheelchair use and 
full-time wheelchair use was taken from 
screening questionnaires.
Exercises were classified based on meta-
bolic equivalents (METs) as moderate 
(MET 3–6) or vigorous (MET >6) (online 
supplementary table 1).3 Participants were 
coded, based on the maximum frequency 
of activity reported between ages 10 and 
18 years, as 0—no physical activity; 1—
vigorous activity occasionally/monthly, 
or moderate activity once weekly; 2— 
moderate activity multiple times per week 
or vigorous activity once weekly; and 3—
vigorous activity multiple times per week.
Statistical analysis
Age of symptom onset was compared by 
analysis of variance (ANOVA) with least 
squares means for individual group differ-
ences. Risk of symptom onset, occasional 
wheelchair use and full-time wheelchair 
requirement over time were compared for 
exercise groups 1, 2 and 3 against group 
0 using Cox proportional hazards regres-
sion. Proportional hazards assumption 
was violated for initial wheelchair use. 
Inspection of survival curves suggested 
this was occurring at later ages; thus, anal-
ysis was rerun censoring at age 50 if there 
was no wheelchair use up to that point, 
which prevented violation of this assump-
tion while capturing 46/55 events.
Interaction between teen exercise level, 
gender and clinical diagnosis was also 
assessed by two-way ANOVA. Subgroups 
of limb girdle muscular dystrophy 2B 
(LGMD2B), Miyoshi myopathy (MM) or 
‘other’ (all genetically confirmed dysferl-
inopathies) were used for analysis.
reSultS
Exercise group 0 had more female patients 
(65%). Demographic characteristics of 
each exercise group were otherwise similar 
(online supplementary table 2).
Age of symptom onset
Estimated mean age of symptom onset 
differed by group (P=0.03) and was later 
in group 0 (mean 24.8 (95% CI 22.3 to 
27.2)) compared with groups 2 (20.2 (18.1 
to 22.3), P=0.006) and 3 (20.6 (18.4 to 
22.8), P=0.01), but not 1 (21.7 (17.7 to 
25.7), P=0.20). Cox regression analysis 
suggested that groups 2 (HR 1.56 (95% 
CI 1.06 to 2.30)) and 3 (HR 1.54 (1.04 
to 2.30)) were at increased risk of earlier 
symptom onset than group 0 (figure 1). 
This was not significant for group 1 (HR 
1.38 (0.78 to 2.45)).
In patients with a clinical diagnosis 
of LGMD2B, groups 1–3 all showed a 
significantly increased risk of earlier onset 
compared with group 0 (1: HR 7.74 (95% 
CI 3.07 to 19.49); 2: HR 1.71 (1.05 to 
2.77); 3: HR 1.91 (1.14 to 3.18)). Signifi-
cant associations were not seen among those 
with a diagnosis of MM or ‘other’.
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Results were independent of gender, 
which was not significantly related to 
age of onset (P=0.329) or exercise group 
(P=0.328).
Wheelchair use
Fifty-five patients reported age at first 
wheelchair use and 42 using a wheelchair 
full time.
Statistical analysis showed a higher 
risk for part-time wheelchair use in exer-
cise groups 2 (HR 3.57 (95% CI 1.36 to 
9.36)) and 3 (HR 5.44 (2.20 to 13.48)) 
compared with group 0; no association 
was noted for group 1 (HR 2.12 (0.53 to 
8.51)).
Greater teenage activity was also asso-
ciated with increased risk of full-time 
wheelchair requirement in group 3 (HR 
4.11 (1.75 to 9.64)). This was not signifi-
cant in groups 1 (HR 0.97 (0.20 to 4.73)) 
or 2 (HR 2.18 (0.82 to 5.75)).
dIScuSSIon
In the present study, patients recalling 
greater teenage exercise levels demonstrated 
increased risk for earlier symptom onset and 
wheelchair requirement. Teenage exercise 
level was chosen as this is typically before 
symptom onset in dysferlinopathy, yet old 
enough for significant exercise regimens 
to have started. Although an association 
between exercise and subsequent disease 
progression has previously been suggested 
by Angelini et al4 Klinge et al2 reported 
no significant effect of exercise on age of 
symptom onset in 36, mostly LGMD2B, 
patients. These studies all rely on patient 
recall, introducing potential question and 
recall bias. We tried to mitigate for this 
using a scoring system based on METs 
rather than Klinge’s use of patient-reported 
sporting level. However, our approach still 
does not produce uniform exercise catego-
ries, requiring grouping of different types 
and frequencies of exercise, which may not 
have equitable physiological impact. Unfor-
tunately, this is the nature of a retrospec-
tive study, which is necessary while so few 
patients are diagnosed presymptomatically.
Exercise is usually considered beneficial 
in muscular dystrophies, and so this finding 
in dysferlinopathy may suggest a unique 
underlying pathological mechanism. Inves-
tigation of this was not within the scope 
of this study. However, previous work has 
suggested that dysferlinopathy may increase 
aptitude for training early in life, but the 
more a patient exercises vigorously, the 
more muscle damage occurs, which is then 
inadequately repaired5—accelerating both 
disease onset and symptom progression.
This study raises implications for 
patients and families. If intensive exercise 
causes earlier onset and faster progression, 
asymptomatic patients should consider 
limiting their exercise and affected siblings 
should be identified to allow for early 
disease-modifying advice. However, as the 
HRs are small, this needs to be balanced 
against the loss of other lifestyle benefits 
of exercise. As we did not look at the 
effects of exercise once symptoms began, 
we would not advocate that symptomatic 
patients stop exercising.
This letter describes an association of 
intensive exercise during the teenage years 
with earlier disease onset and faster rate 
of disease progression in patients with 
dysferlinopathy.
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